EGFR inhibition for recurrent or metastatic HNSCC
Mené dans 19 pays sur 483 patients atteints d'un carcinome épidermoïde de la tête et du cou récidivant ou métastatique, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'afatinib par rapport au méthotrexate en traitement de deuxième ligne
Head and neck squamous-cell carcinoma (HNSCC) is usually localised and potentially curable at initial diagnosis, but often recurs after treatment and can be associated with distant metastasis. Systemic therapy has an integral role in the management of patients with HNSCC; however, by contrast with therapeutic advances seen in other solid tumours, systemic therapy of HNSCC has remained relatively stagnant in recent years with the notable exception of the development of EGFR inhibitors.